Clinical Experiences With the Nitazene Class of Synthetic Opioids: A Cohort Study
This case series highlights that standard parenteral naloxone doses are typically effective, but ongoing monitoring is necessary to detect renarcotization. Nitazene opioids display novel consumption patterns, including exposure by vaping and unintentional use in products sold as containing another drug. The risk of opioid withdrawal from regular nitazene opioid use is a novel observation. Monitoring trends through active drug surveillance, public education, and community access to naloxone are crucial to mitigate the harm posed by nitazene opioid opioids.
Authors
- Christine A. Harvey (ORCID: https://orcid.org/0009-0003-8203-4983)
- Jared A Brown (ORCID: https://orcid.org/0000-0001-6855-3865)
- Darren M. Roberts (ORCID: https://orcid.org/0000-0001-9101-7577)
- Thanjira Jiranantakan (ORCID: https://orcid.org/0000-0002-9546-1939)
- Ben Tisdell
- Mona F Sajeev
Institutions
- New South Wales Department of Health (AU)
- Royal Prince Alfred Hospital (AU)
- Sydney Children’s Hospitals Network (AU)
Publication Details
- Journal
- Annals of Emergency Medicine
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1016/j.annemergmed.2025.06.619
- Citations
- 7
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 13.15